Although fourth-quarter 2020 sales of Roche Holding AG's multiple sclerosis blockbuster Ocrevus were well down on analyst forecasts, the Swiss major is confident about the drug's long-term prospects and its ability to fend off Novartis AG's newly launched rival Kesimpta.
Full-year revenues for Ocrevus (ocrelizumab) were still impressive, rising 24% to CHF4.33bn ($4.80bn) and the fourth quarter contributed CHF1.05bn to...